3Eskew LA, Bare RL, McCullough DL, et al. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the Prostate [J]. J Urol, 1997, 157(1): 199-202.
6Hodge KKMcneal JE, Tenis MK, et al. Randon systematic versus directed ultrasound guided transrectal core biopsies of the prostate [J]. J Urol, 1989,142:71-74.
7Dclivcliotis C, Varkarkis J, Albanis S, et al. Biopsies of the transitional zone of the prostate. Should it bc done on a routine basis, when and why? [J]. J Urol, 2002, 68(2): 113-117.
二级参考文献32
1Greenlee RT, Murray, Bolden, et al. Cancer statistics. CA Cancer J clin,2001,51 : 15-36.
2Lee F, Torp Pedersen ST, Siders DB, et al. Transrectal ultrasound in diagnosis and staging of prostatic carcinoma. Radiology, 1959,170 : 609-615.
3Kravchick S, Cytron S, Pytel A, et al. Improved detection of clinically significant curable prostate cancer with systematicl2 corebiopsy. TU rol,2004,171:1089.
4Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy:a prospective study and review of the literature. J Urol, 1998,160:2115-2120.
5Karnoi K, Troncoso P, Babaian, RJ. Strategy for repeat biopsy inpatients with high grade prostatic intraepithelial neoplasia. J Urol,2000,163(3) :819-823.
6Rodriguez Patron Rodriguez R, Mayayo Dehesa T, Gonzalez Galan A, et al. Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy?Study on 546 patients who underwent repeated biopsy. Arch Esp Urol,2002, 55(10) :225-234.
7Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 1998, 279(19) : 1542-1547.
8Uzzo RG, Pinover WH, Horwitz EM, et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Urology,2003,61 (4) :754-759.
9Gomez De Vicente JM, Lujan Galan M, Paez Borda A, et al. Detection of prostatic cancer in the PSA range between 3 and 3.9 ng/ml. Actas Urol Esp, 2002,26(4) :271-274.
10Punglia RS, D' Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med,2003,349(4) :335-342.
1Singh H, Canto EI, Shariat SF, et al. Improved detection of clinically significant,curable prostate cancer with systematic 12-core biopsy[J].Urol, 2004,171:1089-1092.
2Applewhite JC, Matlaga BR, McCullough DL. Results of the 5 region prostate biopsy method: the repeat biopsy population[J]. Urol, 2002, 168:500-503.
